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Abstract
Rationale: Early evaluation of the burden of disease that
COVID-19 may produce in a community is critical to appropriately allocate resources for COVID-19 prevention and treatment.
Objective: The primary objective of this study is to define
the incidence, epidemiology, and clinical outcomes of patients

Background and Significance
The World Health Organization (WHO) declared
COVID-19 a pandemic on March 11, 2020.[1] The virus
that causes COVID-19 is SARS-CoV-2. It is expected
that SARS-CoV-2 will reach global spread and will infect a significant number of the global population. The
declaration of a pandemic refers primarily to the capability of SARS-CoV-2 to spread from person to person
at a global level, but the declaration of pandemic is not
related to the severity of SARS-CoV-2. The burden of
patients with COVID-19 may vary from region to region. This variability is primarily due to the mutations
that SARS-CoV-2 will accumulate as the virus moves
through the population. When the virus mutates, it undergoes small changes in its genome. A common pattern of evolution for viral infections is that as the virus
mutates, it may have the capability to spread more efficiently from person to person, and at the same time,
the strain may become less aggressive, which results
in better outcomes in patients with the disease. Even
though this is the most likely evolution of a virus, we
do not know if the new mutations of SARS-CoV-2 will
produce a virus more virulent or less virulent. At the
present time, there are different patterns of burden of
disease originating in China [2], Italy [3], and Germany
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with COVID-19 in the Louisville, Kentucky, and southern Indiana region (Kentuckiana) of the USA.
Methods: This will be a retrospective observational study
of patients in the Kentuckiana region with the diagnosis of
COVID-19.

[4]. Why the clinical outcomes of patients with COVID19 in these regions are different is unclear, but different
viral mutations may partially explain the clinical outcomes.
Because of the above, it is clear that it will be difficult to predict the burden of COVID-19 in the city of
Louisville, Kentucky and the surrounding area, regularly referred to as the Kentuckiana region, based on
burden of disease from other regions. Defining burden of disease as soon as possible after SARS-CoV-2 arrives in the region is critical to properly inform public
health authorities for development of effective preventive strategies, and healthcare professionals so they are
able to appropriately and safely manage and treatment
patients with COVID-19.
In an attempt to identify early burden of disease in Kentuckiana, the primary objective of this study is to define
the incidence, epidemiology, and clinical outcomes of
patients diagnosed with COVID-19 in Kentuckiana.
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Objectives

Mortality

Primary Objectives
1. To define the incidence, epidemiology, and clinical
outcomes of patients in Kentuckiana diagnosed with
COVID-19.

All-cause mortality for all COVID-19 patients will be
evaluated at 30-days, 6-months, and 1-year after diagnosis. Mortality data will be obtained from the Kentucky Department for Public Health Office of Vital
Statistics.

Secondary Objectives

Scientific Advisory Board

1. To evaluate incidence of COVID-19 in special populations.

3. To define areas of the community where surveillance
activities should be increased.

A scientific advisory board has been established with
leaders from Kentuckiana health care systems. The
board has the following objectives: 1) To provide feedback for improvement of the Burden of COVID-19
study; 2) To support the dissemination of information.
Regular meetings will be held by the principal investigator and members of the scientific advisory board.

4. To rapidly disseminate the new knowledge gained
by this project.

Preliminary Studies

2. To evaluate better inform Public Health authorities
of local COVID-19 activity.

Methods
Study Design and Subjects
The Burden of COVID-19 study will be a retrospective cohort study of all patients in the Kentuckiana region with diagnosis of COVID-19, and has been approved by the University of Louisville Institutional Review Board as #20-0257.
Inclusion and Exclusion Criteria
A patient will be defined as having COVID-19 when
the virus SARS-CoV-2 was identified in a clinical specimen using Polymerase Chain Reaction (PCR). All patients with diagnosis of COVID-19 will be evaluated.
The study will have no exclusion criteria.
Incidence Calculations
The monthly COVID-19 incidence rates per 100,000
adults will be estimated for: unique patients (unadjusted and age-adjusted), total hospitalizations, unique
patients by various age groups, unique patients by comorbid conditions and smoking status, as well as for
white and black/African American races.
Geospatial Epidemiology
To define specific hot areas with high density of
COVID-19 in Kentuckiana, initially the geomasked location of each patient’s home address will be obtained
through the US Census Bureau website. A Kernel Density heatmap will be created. Kuldorff’s Spatial Scan
Statistic will be used to calculate significant areas of
risk for COVID-19. Choropleth maps will be created to
compare census tract-level demographics and the spatial distribution of COVID-19 cases.
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The principal investigator, Dr. Julio Ramirez, has
vast experience in development and implementation of
studies evaluating burden of particular infectious diseases.
Dr. Ramirez is the Chief of the Division of Infectious
Diseases and Director of the Center of Excellence for
Research in Infectious Diseases (ceridlouisville.org).
He has led multiple surveillance programs in the State
of Kentucky, including the Severe Influenza Pneumonia Surveillance (SIPS) Project. SIPS was funded by
the Department of Homeland Security.[5] He was also
funded by the Centers for Disease Control and Prevention to study the role of oseltamivir in hospitalized patients with influenza in the city of Louisville. This was
done in collaboration of CERID with all adult hospitals
in Louisville.[6] More recently, Pfizer Pharmaceuticals
sponsored CERID to perform a population-based study
of all hospitalized adult patients in the city of Louisville
to define the burden of community-acquired pneumonia. Data from this study were used to estimate the
burden of pneumonia in the United States.[7] The successes of these studies led to the selection of CERID as
the North American Center of Excellence for Vaccine
Epidemiology, funded by Pfizer. This is the first such
center in the world, and recognizes the unique infrastructure and capabilities of UofL CERID (Center of Excellence annoucement).

Project Coordinating Center
The Burden of COVID-19 study will be coordinated by
the Center of Excellence for Research in Infectious Diseases (CERID). The current structure of CERID is depicted in Figure 1. The activities related to this project
for each of the CERID units are as follows:
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Figure 1. Structure of the project coordinating center.

Data Management Unit: generate the data collection
form and the Research Electronic Data Capture (REDCap) database for this project.
Implementation Unit: responsible for data collection,
and data entry into the REDCap database.
Laboratory Unit: no activity related to this retrospective study.
Biostatistics Unit: will be responsible for periodic and
real-time analysis of incidence, epidemiological, and
clinical outcomes data.
Medical Writing Unit: will support the generation of
manuscripts.
Peer-Review Journals Unit: will facilitate rapid publication of new knowledge.
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Informatics Unit: will support the data management
unit and implementation unit in regard to computer
and database maintenance.
Community Outreach Unit: will be responsible for
maintaining open lines of communication with community leaders and coordinating activities of the Advisory Board.
University Outreach Unit: will be responsible for
maintaining open lines of communication with UofL
leaders and will work with the Community Outreach
Unit to coordinate the activities of the Advisory Board.
Marketing Unit: will collaborate with investigators to
develop education and response communications.
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Protection of Human Subjects
All patient information will be entered into REDCap
databases, which are Health Insurance Portability and
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Appendix: Burden of COVID-19 Scientific Advisory Board
University of Louisville Center of Excellence for Research in Infectious Diseases
Ruth Carrico, PhD; Leslie Wolf, PhD
University of Louisville Center for Predictive Medicine
Kenneth E. Palmer PhD; Donghoon Chung, PhD
University of Louisville School of Public Health
William McKinney, MD
Louisville Public Health
Sarah Moyer, MD
University of Louisville Health
Jason Smith, MD; Forest W. Arnold, DO
Norton Healthcare Louisville
James Frazer, MD; Paul Schulz, MD; Ashley Wilde, PharmD
Baptist Health Louisville
Kenneth Anderson, MD; Anna Hart, MD
Clark Memorial Health
Klaus Boel, MD
Floyd Memorial Hospital
Krishna Konijeti, MD
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